Marine natural products as targeted modulators of the transcription factor NF-κB

Biochemical Pharmacology

Volumn 75, Issue 3, 2008, Pages 603-617

  Folmer, Florence ^a   Jaspars, Marcel ^a   Dicato, Mario ^b   Diederich, Marc ^b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b HÔpital Kirchberg   (Luxembourg)

Author keywords

Cell signalling; Drug discovery; Marine compounds; Natural product; NF kappaB

Indexed keywords

1 O (ALPHA GALACTOPYRANOSYL) 2 HEXACOSANOYLAMINO 1,3,4 OCTADECANETRIOL; 4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; AE 941; ALPHA TOCOPHEROL; ANALGESIC AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; ARSENOSOBENZENE; ASCORBIC ACID; AURISTATIN PE; BENZOQUINONE HERBIMYCIN A; BORTEZOMIB; CRYPTOPHYCIN 52; E 7389; ES 285; GALLIC ACID; GELDANAMYCIN; HELENALIN; HERBIMYCIN A; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IPL 576092; LACTACYSTIN BETA LACTONE; NATURAL PRODUCT; PANEPOPHENANTHRIN; PARTHENOLIDE; POLYPHENOL DERIVATIVE; PROTEASOME INHIBITOR; RESVERATROL; SALICYLATE SODIUM; SALINOSPORAMIDE A; SELENIUM DERIVATIVE; SESQUITERPENE LACTONE; TALTOBULIN; THALIDOMIDE; TRABECTEDIN; TRANSCRIPTION FACTOR; TRITERPENE; UBIDECARENONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; ASTRONOMY; BIOLOGY; BIOMEDICAL ENGINEERING; CELL SURVIVAL; CLINICAL TRIAL; DRUG MECHANISM; EXPLORATORY RESEARCH; GENE TARGETING; HUMAN; IMMUNE SYSTEM; INVERTEBRATE; MARINE ENVIRONMENT; MULTIPLE MYELOMA; NEOPLASM; NONHUMAN; PRIORITY JOURNAL;

EID: 37849022679     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.07.044     Document Type: Note

References (96)

1. Nagle D.G., Zhou Y.D., Mora F.D., Mohammed K.A., and Kim Y.P. Mechanism targeted discovery of antitumor marine natural products. Curr Med Chem 11 (2004) 1725-1756
2. Newman D.J., and Cragg G.M. Marine natural products and related compounds in clinical and advanced preclinical trials. J Nat Prod 67 (2004) 1216-1238
3. Agarwal R., Agarwal C., Ichikawa H., Singh R.P., and Aggarwal B.B. Anticancer potential of silymarin: from bench to bed side. Anticancer Res 26 (2006) 4457-4498
4. Faulkner D.J. Marine pharmacology. Antonie Van Leeuwenhoek 77 (2000) 135-145
5. Aggarwal B.B., Takada Y., Shishodia S., Gutierrez A.M., Oommen O.V., Ichikawa H., et al. Nuclear transcription factor NF-kappa B: role in biology and medicine. Indian J Exp Biol 42 (2004) 341-353
6. Karin M. Nuclear factor-kB in cancer development and progression. Nature 441 (2006) 431-436
7. Pikarsky E., Porat R.M., Stein I., Abramovitch R., Amit S., Kasem S., et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431 (2004) 461-466
8. Sebolt-Leopold J., and English J. Mechanisms of drug inhibition of signalling molecules. Nature 441 (2006) 457-462
9. Darnell Jr. J.E. Transcription factors as targets for cancer therapy. Nat Rev Cancer 2 (2002) 740-749
10. Karin M., and Greten F.R. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5 (2005) 749-759
11. Keutgens A., Robert I., Viatour P., Chariot A., and Deregulated. NF-κB activity in haemological malignancies. Biochem Pharmacol 72 (2006) 1069-1080
12. Evans P. Regulation of pro-inflammatory signalling networks by ubiquitin: identification of novel targets for anti-inflammatory drugs. Exp Rev Mol Med 7 (2005) 1-19
13. Sun L., and Chen Z.J. The novel functions of ubiquitination in signaling. Curr Opin Cell Biol 16 (2004) 119-126
14. Chen Z.J. Ubiquitin signalling in the NF-kappaB pathway. Nat Cell Biol 7 (2005) 758-765
15. Blonska M., Shameshakar P., Kobayashi M., Zhang D., Sakurai H., Su B., et al. TAK1 is recruited to the tumor necrosis factor-alpha (TNF-alpha) receptor 1 complex in a receptor-interacting protein (RIP)-dependent manner and cooperates with MEKK3 leading to NF-kappa B activation. J Biol Chem 280 (2005) 43056-43063
16. Whiteside S.T., and Israel A. I kappa B proteins: structure, function and regulation. Semin Cancer Biol 8 (1997) 75-82
17. Hsu H., Huang J., Shu H., Baichwal V., and Goeddel D.V. TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity 4 (1996) 387-396
18. Beinke S., and Ley S.C. Functions of NF-κB1 and NF-κB2 in immune cell biology. Biochem J 382 (2004) 393-409
19. Tergaonkar V., Bottero V., Ikawa M., Li Q., and Verma I.M. IκB kinase-independent IκBα degradation pathway: functional NF-κB activity and implications for cancer therapy. Mol Cell Biol 23 (2003) 8070-8083
20. Li N., and Karin M. Ionizing radiation and short wavelength UV activate NF-κB through two distinct mechanisms. Proc Natl Acad Sci USA 95 (1998) 13012-13017
21. Schwarz E., Van Antwerp D., and Verma I.M. Constitutive phosphorylation of IκBα by casein kinase II occurs preferentially at serine 293: requirement for degradation of free IκBα. Mol Cell Biol 16 (1996) 3554-3559
22. Bremner P., and Heinrich M. Natural products as targeted modulators of the nuclear factor-kappa B pathway. J Pharm Pharmacol 54 (2002) 453-472
23. Rungeler P., Castro V., Mora G., Goren N., Vichnewski W., Pahl H.L., et al. Inhibition of transcription factor NF-kappa B by sesquiterpene lactones: a proposed molecular mechanism of action. Bioorg Med Chem 7 (1999) 2343-2352
24. Garcia-Pineres A.J., Castro V., Mora G., Schmidt T.J., Strunck E., Pahl H.L., et al. Cysteine 38 in p65/NF-kappa B plays a crucial role in DNA binding inhibition by sesquiterpene lactones. J Biol Chem 276 (2001) 39713-39720
25. Clayden J., Greeves N., Warren S., and Wothers P. Organic chemistry (2001), Oxford University Press, Oxford
26. Pande V., Sharma R.K., Inoue J.I., Otsuka M., and Ramos M.J. A molecular modeling study of inhibitors of nuclear factor kappa-B (p50) - DNA binding. J Comput-Aided Mol Design 17 (2003) 825-836
27. Delcros J.G., Baudy Floc'h M., Prigent C., and Arlot-Bonnemains Y. Proteasome inhibitors as therapeutic agents: current and future strategies. Curr Med Chem 10 (2003) 479-503
28. Shah I.M., Lees K.R., Pien C.P., and Elliott P.J. Early clinical experience with the novel proteasome inhibitor PS-519. Br J Clin Pharmacol 54 (2002) 269-276
29. Karin M., Yamamoto Y., and Wang Q.M. The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Disc 3 (2004) 17-26
30. Banerjee D., and Liefshitz A. Potential of the proteasome inhibitor MG-132 as an anticancer agent, alone and in combination. Anticancer Res 21 (2001) 3941-3947
31. Shah S.A., Potter M.W., and Callery M.P. Ubiquitin proteasome inhibition and cancer therapy. Surgery 131 (2002) 595-600
32. Sun Y. Targeting E3 ubiquitin ligases for cancer therapy. Cancer Biol Ther 2 (2003) 623-629
33. Li H., Kobayashi M., Blonska M., Yon Y., and Lin X. Ubiquitination of RIP is required for tumor necrosis factor alpha-induced NF-kappa B activation. J Biol Chem (2006) 281
34. Mukhopadhyay D., and Riezman H. Proteasome-independent functions of ubiquitin in endocytosis and signaling. Science 315 (2007) 201-205
35. Hochstrasser M. Lingering mysteries of ubiquitin-chain assembly. Cell 124 (2006) 27-34
36. Sekizawa R., Ikeno S., Nakamura H., Naganawa H., Matsui S., Iinuma H., et al. Panepophenanthrin, from a mushroom strain, a novel inhibitor of the ubiquitin-activating enzyme. J Nat Prod 65 (2002) 1491-1493
37. Tsukamoto S., Hirota H., Imachi M., Fujimuro M., Onuki H., Ohta T., et al. Himeic acid A: a new ubiquitin-activating enzyme inhibitor isolated from a marine-derived fungus, Aspergillus sp. Bioorg Med Chem Lett 15 (2005) 191-194
38. Berleth E.S., Kasperek E.M., Grill S.P., Braunscheidel J.A., Graziani L.A., and Pickart C.M. Inhibition of ubiquitin-protein ligase (E3) by mono- and bifunctional phenylarsenoxides. Evidence for essential vicinal thiols and a proximal nucleophile. J Biol Chem 267 (1992) 16403-16411
39. Ogino S., Tsuruma K., Uehara T., Nomura Y., and Herbimycin. A abrogates nuclear factor-kappaB activation by interacting preferentially with the IkappaB kinase beta subunit. Mol Pharmacol 65 (2004) 1344-1351
40. Shrivastava A., and Aggarwal B.B. Antioxidants differentially regulate activation of Nuclear Factor-κB, activator protein-1, c-Jun amino-terminal kinases, and apoptosis induced by tumor necrosis factor: evidence that JNK and NF-κB activation are not linked to apoptosis. Antiox Redox Signal 1 (1999) 181-191
41. Palladino M.A., Bahjat F.R., Theodorakis E.A., and Moldawer L.L. Anti-TNF-alpha therapies: the next generation. Nat Rev Drug Disc 2 (2003) 736-746
42. Takamatsu S., Hodges T.W., Rajbhandari I., Gerwick W.H., Hamann M.T., and Nagle D.G. Marine natural products as novel antioxidant prototypes. J Nat Prod 66 (2003) 605-608
43. Kopp E.B., and Ghosh S. Inhibition of NF-κB by sodium-salicylate and aspirin. Science 265 (1994) 956-959
44. Garcia-Pineres A.J., Lindenmeyer M.T., and Merfort I. Role of cysteine residues of p65/NF-kappa B on the inhibition by the sesquiterpene lactone parthenolide and-N-ethyl maleimide, and on its transactivating potential. Life Sci 75 (2004) 841-856
45. Siedle B., Garcia-Pineres A.J., Murillo R., Schulte-Monting J., Castro V., Rungeler P., et al. Quantitative structure - activity relationship of sesquiterpene lactones as inhibitors of the transcription factor NF-kappa B. J Med Chem 47 (2004) 6042-6054
46. Folmer F., Blasius R., Morceau F., Tabudravu J., Dicato M., Jaspars M., et al. Inhibition of TNFα-induced activation of nuclear factor κB by kava (Piper methysticum) derivatives. Biochem Pharmacol 71 (2006) 1206-1218
47. Zambre A.P., Kulkarni V., Padhye S., Sandur S.K., and Aggarwal B.B. Curcumin analogs targeting TNF-induced NF-κB activation and proliferation in human leukemic KBM-5 cells. Bioorg Med Chem 14 (2006) 7196-7204
48. Ludwig H., Khayat D., Giaccone G., and Facon T. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer 104 (2005) 1794-1807
49. Dy G.K., Thomas J.P., Wilding G., Bruzek L., Mandrekar S., Erlichman C., et al. A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer. Clin Cancer Res 11 (2005) 3410-3416
50. Roth M., and Black J.L. Transcription factors in asthma: are transcription factors a new target for asthma therapy?. Curr Drug Targets 7 (2006) 589-595
51. Aggarwal B.B., and Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 71 (2006) 1397-1421
52. Scheuer P.J. Some marine ecological phenomena - chemical basis and biomedical potential. Science 248 (1990) 173-177
53. Pancer Z., Rast J.P., and Davidson E.H. Origins of immunity: transcription factors and homologues of effector genes of the vertebrate immune system expressed in sea urchin coelomocytes. Immunogenetics 49 (1999) 773-786
54. Schlezinger J.J., Blickarz C.E., Mann K.K., Doerre S., and Stegeman J.J. Identification of NF-kappaB in the marine fish Stenotomus chrysops and examination of its activation by aryl hydrocarbon receptor agonists. Chem Biol Interact 126 (2000) 137-157
55. Muller W.E., Gamulin V., Rinkevich B., Spreitzer I., Weinblum D., and Schroder H.C. Ubiquitin and ubiquitination in cells from the marine sponge Geodia cydonium. Bio Chem Hoppe-Seyler 375 (1994) 53-60
56. Wang X.W., Tan N.S., Ho B., and Ding J.L. Evidence for the ancient origin of the NF-{kappa}B/I{kappa}B cascade: its archaic role in pathogen infection and immunity. Proc Natl Acad Sci USA 103 (2006) 4204-4209
57. Povelones M., Tran K., Thanos D., and Ambron R.T. An NF-kappaB-like transcription factor in axoplasm is rapidly inactivated after nerve injury in Aplysia. J Neurosci 17 (1997) 4915-4920
58. Merlo E., Freudenthal R., and Romano A. The I kappa B kinase inhibitor sulfasalazine impairs long-term memory in the crab Chasmagnathus. Neuroscience 112 (2002) 161-172
59. Friedman R., and Hughes A.L. Molecular evolution of the NF-kappaB signaling system. Immunogenetics 53 (2002) 964-974
60. Escoubas J.M., Briant L., Montagnani C., Hez S., Devaux C., and Roch P. Oyster IKK-like protein shares structural and functional properties with its mammalian homologues. FEBS Lett 453 (1999) 293-298
61. Shimada M., Satoh N., and Yokosawa H. Involvement of Rel/NF-kappaB in regulation of ascidian notochord formation. Dev Growth Differ 43 (2001) 145-154
62. Hiscott J., Kwon H., and Genin P. Hostile takeovers: viral appropriation of the NF-kappa B pathway. J Clin Invest 107 (2001) 143-151
63. Lisowska K., and Witkowski J.M. Viral strategies in modulation of NF-kappaB activity. Arch Immunol Ther Exp 51 (2003) 367-375
64. Romano G., Russo G.L., Buttino I., Ianora A., and Miralto A. A marine diatom-derived aldehyde induces apoptosis in copepod and sea urchin embryos. J Exp Biol 206 (2003) 3487-3494
65. Stevenson C.S., Capper E.A., Roshak A.K., Marquez B., Eichman C., Jackson J.R., et al. The identification and characterization of the marine natural product scytonemin as a novel antiproliferative pharmacophore. J Pharmacol Exp Ther 303 (2002) 858-866
66. Rawat D.S., Joshi M.C., and Atheaya H. Marine peptides and related compounds in clinical trial. Anticancer Agents Med Chem 6 (2006) 33-40
67. Simmons T.L., Andrianasolo E., McPhail K., Flatt P., and Gerwick W.H. Marine natural products as anticancer drugs. Mol Cancer Ther 4 (2005) 333-342
68. Jimeno J., Faircloth G., Fernandez Sousa-Faro J.M., Scheuer P.J., and Rinehart K.L. New marine derived anticancer therapeutics - a journey from the sea to clinical trials. Mar Drugs 2 (2004) 14-29
69. Newman D.J., and Cragg G.M. Advanced preclinical and clinical trials of natural products and related compounds from marine sources. Curr Med Chem 11 (2004) 1693-1713
70. Haefner B. Drugs from the deep: marine natural products as drug candidates. Drug Discovery Today 8 (2003) 536-544
71. Posadas I., De Rosa S., Terencio M.C., Paya M., and Alcaraz M.J. Cacospongionolide B suppresses the expression of inflammatory enzymes and tumour necrosis factor-alpha by inhibiting nuclear factor-kappa B activation. Br J Pharmacol 138 (2003) 1571-1579
72. Macherla V.R., Mitchell S.S., Manam R.R., Reed K.A., Chao T.H., Nicholson B., et al. Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor. J Med Chem 48 (2005) 3684-3687
73. Tsukamoto S., Koimaru K., and Ohta T. Secomycalolide A: a new proteasome inhibitor isolated from a marine sponge of the genus Mycale. Mar Drugs 3 (2005) 29-35
74. Tsukamoto S., Tatsuno M., van Soest R.W., Yokosawa H., and Ohta T. New polyhydroxy sterols: proteasome inhibitors from a marine sponge Acanthodendrilla sp. J Nat Prod 66 (2003) 1181-1185
75. D'Acquisto F., Lanzotti V., and Carnuccio R. Cyclolinteinone, a sesterterpene from sponge Cacospongia linteiformis, prevents inducible nitric oxide synthase and inducible cyclo-oxygenase protein expression by blocking nuclear factor-kappa B activation in J774 macrophages. Biochem J 346 (2000) 793-798
76. Breton J.J., and Chabot-Fletcher M.C. The natural product hymenialdisine inhibits interleukin-8 production in U937 cells by inhibition of nuclear factor-kappaB. J Pharmacol Exp Ther 282 (1997) 459-466
77. Kamata K., Okamoto S., Oka S., Kamata H., Yagisawa H., and Hirata H. Cycloprodigiosin hydrochloride suppresses tumor necrosis factor (TNF) alpha-induced transcriptional activation by NF-kappa B. FEBS Lett 507 (2000) 74-80
78. Oda T., Namikoshi K., Akamo K., Honma Y., Kasahara T., and Verrucarin. A inhibition of MAP kinase activation in a PMA-stimulated promyelocytic leukemia cell line. Mar Drugs 3 (2005) 64-73
79. Lu P.H., Chuch S.C., Kung F.L., Pan S.L., Shen Y.C., and Guh J.H. Ilimaquinone, a marine metabolite, displays anticancer activity via GADD153-mediated pathway. Eur J Pharmacol 556 (2007) 45-54
80. Catassi A., Cesario A., Arzani D., Menichini P., Alama A., Bruzzo C., et al. Characterization of apoptosis induced by marine natural products in non small cell lung cancer A549 cells. Cell Mol Life Sci 63 (2006) 2377-2386
81. Hong S., Kim S.H., Rhee M.H., Kim A.R., Jung J.H., Chun T., et al. In vitro anti-inflammatory and pro-aggregative effects of a lipid compound, petrocortyne A, from marine sponges. Naunyn Schmiedebergs Arch Pharmacol 368 (2003) 448-456
82. Takada Y., Khuri F., and Aggarwal B.B. Protein farnesyltransferase inhibitor (SCH 66336) abolishes NF-κB activation induced by various carcinogens and inflammatory stimuli leading to suppression of NF-κB-regulated gene expression and up-regulation of apoptosis. J Biol Chem 279 (2004) 26287-26299
83. Jeong S.J., Pise-Masison C.A., Radonvich M.F., Park H.U., and Brady J.N. Activated AKT regulates NF-κB activation, p53 inhibition, and cell survival in HTLV-1-transformed cells. Oncogene 24 (2005) 6719-6728
84. Romashkova J.A., and Makarov S.S. NF-kappaB is a target of Akt in anti-apoptotic PDGF signalling. Nature 401 (1999) 86-90
85. Tamarkin F.J., Kang W.S., Cohen J.J., Wheeler M.A., and Weiss R.M. A role for Akt in the rapid regulation of inflammatory and apoptotic pathways in mouse bladder. Naunyn Schmiedebergs Arch Pharmacol 373 (2006) 349-359
86. Xie Y., Liu L., Huang X., Guo Y.W., and Lou L. Scalaradial inhibition of epidermal growth factor receptor-mediated Akt phosphorylation is independent of secretory phospholipase A2. J Pharmacol Exp Ther 314 (2005) 1210-1217
87. Potts B.C., Faulkner D.J., and Jacobs R.S. Phospholipase A2 inhibitors from marine organisms. J Nat Prod 55 (1992) 1701-1717
88. Nevalainen T.J., Quinn R.J., and Hooper J.N. Phospholipase A2 in porifera. Comp Biochem Physiol B 137 (2004) 413-420
89. Terracciano S., Rodriquez M., Aquino M., Monti M.C., Casapullo A., Riccio R., et al. Chemistry and biology of anti-inflammatory marine natural products: molecules interfering with cyclo-oxygenase, NF-κB and other unidentified targets. Curr Med Chem 13 (2006) 1947-1969
90. Thommesen L., Sjursen W., Gasvik K., Hanssen W., Brekke O., Skattebol L., et al. Selective inhibitors of cytosolic or secretory phospholipase A2 block TNF-induced activation of transcription factor nuclear factor-kappaB and expression of ICAM-1. J Immunol 161 (1998) 3421-3430
91. Yang L., Williams D.E., Mui A., Ong C.N., Krystal G., Van Soest R., et al. Synthesis of pelorol and analogues: activators of the inositol 5-phosphatase SHIP. Org Lett 7 (2005) 1073-1076
92. Gloire G., Charlier E., Rahmouni S., Volanti C., Chariot A., Erneux C., et al. Restoration of SHIP-1 activity in human leukemic cells modifies NF-κB activation pathway and cellular survival upon oxidative stress. Oncogene 25 (2006) 5485-5494
93. Jensen P.R., Mincer T.J., Williams P.G., and Fenical W. Marine actinomycete diversity and natural product discovery. Antonie Van Leeuwenhoek 87 (2005) 43-48
94. Salomon C.E., Magarvey N.A., and Sherman D.H. Merging the potential of microbial genetics with biological and chemical diversity: an even brighter future for marine natural product drug discovery. Nat Prod Rep 21 (2004) 105-121
95. Dunlap W.C., Jaspars M., Hranueli D., Battershill C.N., Peric-Concha N., Zucko J., et al. New methods for medicinal chemistry - universal gene cloning and expression systems for production of marine bioactive metabolites. Curr Med Chem 13 (2006) 697-710
96. Larsen T., Smedsgaard J., Nielsen K., Hansen M., and Frisvad J. Phenotypic taxonomy and metabolite profiling in microbial drug discovery. Nat Prod Rep 22 (2005) 672-695